Pay in 4 interest-free payments of $6.30 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
Consult your healthcare provider if cycles are absent for more than three months or if you are planning pregnancy
IL-6: More specific to the inflammatory pathways tirzepatide targets
1 Although it has not yet been approved for obesity, tirzepatide has been incorporated in the 2023 ADA guidelines and categorized as very high efficacy for weight loss
Levels of TNF- and soluble TNF receptors in normal-weight, overweight and obese patients with dilated non-ischemic cardiomyopathy: does Anti-TNF therapy still have potential to be used in heart failure depending on BMI
Safety Considerations and Side Effects Whilst GLP-1 receptor agonists demonstrate good overall tolerability, patients and prescribers must understand potential adverse effects and safety considerations, particularly for menopausal women who may have age-related comorbidities
US$ 29.80
US$ 28.94
US$ 20.96
US$ 29.85
US$ 28.72
US$ 25.86
